Selank: 2025 pancreatic-injury patent — RU2833679C1
Николай Алексеевич Смирнов, Александр Леонидович Хохлов, Елена Игоревна Самарина, Сергей Владимирович Куликов, Владимир Николаевич Федоров, Татьяна Алимовна Зубова · 2025 · RU2833679C1 · patent family RU2833679C1
Published 2025-01-28.
Reported patent results
Narrative findings; numerical extraction incomplete
The patent describes less pancreatic inflammation and structural damage during Selank treatment.
Selank preclinical pancreatic-injury experiments in rats; tissue histology and biochemical outcomes, not autoimmune or human pancreatic disease.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Histology | Purulent inflammatory changes were absent in the treated tissue examples; stromal inflammatory proliferation and islet sclerosis were reduced | Rat toxic-injury models; numerical histological scores not transcribed |
| Islet preservation | Islet-area preservation described with both administration routes | The narrative describes similar effects; no formal equivalence analysis established |
The quantitative figure values and complete group sizes were not extracted. Histological protection in toxic injury cannot establish treatment of human diabetes or autoimmune pancreatitis.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. The patent proposes Selank in toxic pancreatic-injury research with animal-model support.
Toxic injury in rats does not establish treatment of diabetes, autoimmune pancreatitis or human pancreatic disease.
- Publication
- RU2833679C1 ↗ · 2025-01-28
- Earliest priority / filing
- Not established / 2023-09-15
- Original applicant / assignee
- Акционерное общество "Инновационный научно-производственный центр "Пептоген"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Use of thr-lys-pro-arg-pro-gly-pro peptide for protection of insular pancreas and exocrine section thereof from toxic destructive effects
Inventors: Николай Алексеевич Смирнов; Александр Леонидович Хохлов; Елена Игоревна Самарина; Сергей Владимирович Куликов; Владимир Николаевич Федоров; Татьяна Алимовна Зубова.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Toxic injury in rats does not establish treatment of diabetes, autoimmune pancreatitis or human pancreatic disease.
- The quantitative figure values and complete group sizes were not extracted. Histological protection in toxic injury cannot establish treatment of human diabetes or autoimmune pancreatitis.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-RU2833679C1. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Николай Алексеевич Смирнов, Александр Леонидович Хохлов, Елена Игоревна Самарина, Сергей Владимирович Куликов, Владимир Николаевич Федоров, Татьяна Алимовна Зубова. Selank: 2025 pancreatic-injury patent — RU2833679C1 RU2833679C1 · patent family RU2833679C1 2025.
Molekul research summary: https://molekul.io/research/patent-ru2833679c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry